Department of Gynaecology and Obstetrics
Aarhus, 8200, Denmark
NCT Number: NCT04994834
A mono center, open label, pilot study in term newborn infants. The study will investigate the effect of supplementation with probiotics on the presence of total Bifidobacterium in the infant feces.
Looking for future studies?
Notify Me0 day–2 month
All sexes
Interventional
Not applicable
Aarhus, 8200, Denmark
The four weeks intervention starts within 24 hours after birth of the study subject and the investigational product will be given for 28 days, followed by a two weeks follow-up period without any intake of the investigational product.
During the entire study period, five visits are scheduled. Visit 2 to Visit 5 are home visits by the study midwife. From Visit 2 and throughout the study period (Visit 2 to Visit 5) the parents will be asked to complete a diary daily.
Infant stool samples will be collected on multiple occasions during the study, as well as maternal breast milk samples, stool and urine samples and samples from vagina. In addition, sample from placenta, umbilical cord, umbilical cord blood and amnion fluid will be collected. Mothers will be asked to complete electronic questionnaires daily during the course of the study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Infants to be enrolled at birth.
Inclusion criteria
for Infants (study subjects)
Pregnant women:
Exclusion criteria
for Infants (study subjects)
Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
Time frame: 28 days after birth
Presence of the investigational product in infant fecal samples after 4 weeks of supplementation (Visit 4) using PCR
Time frame: Baseline, Day14, Day 28
Total fecal Bifidobacterium in infant fecal samples after 4 weeks supplementation Quantification of total Bifidobacterium will be determined by PCR.
Time frame: Baseline, Day 14, Day 28
Characterization of the infant intestinal microbiota after 4 weeks supplementation of the investigational product using sequencing
Time frame: up to 6 weeks
Frequency and severity of adverse events
Time frame: Baseline
Characterization of mother's microbiota from fecal samples will be assessed using sequencing to examine the microbiota for similarities with the infant
Time frame: 42 days
Infant Gastrointestinal Problems will be measured using ROME IV Diagnostic Questionnaires for Pediatric Functional Gastrointestinal Disorders for Neonates and Toddlers: Parent-Report Form for Neonates Section A - Infant Gastrointestinal Problems
Time frame: 42 days
Infant stool frequency and consistency will be measured using Amsterdam Stool Chart.
Time frame: 42 days
Reflux will be measured using Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R)
Time frame: Baseline, Day 14, Day 28
Microbiome of the breastmilk to be assessed using sequencing to explore a potential microbiota of the breastmilk
Time frame: Baseline
Characterization of mother's vaginal microbiota will be assessed using sequencing to examine the microbiota for similarities with the infant
Chr Hansen
Industry
Characterization of the Gastrointestinal Microbiota in Term Newborn Infants After 4 Weeks Supplementation of Probiotics - an Open Label Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06638606
Anxiety, Anxiety Disorders
Tehran, Iran
View Trial DetailsNCT07597811
Dietary Behaviors, Gut Microbiota
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT07112248
Gut Microbiota, Obesity-related Poor Sperm Quality
Wuhan, Hubei, China
View Trial DetailsNCT07194772
Glucose Homeostasis, Glucose Intolerance
Ottawa, Ontario, Canada
View Trial Details